Asia
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
Ai in medical field is helping the researchers at clinical stage research by increasing the efficiency, refining endpoints and quantifying pain, and much more.
Using gene therapy to edit embryos, sperm or eggs in order to improve health conditions in a child should not be conducted due to the unreliability of the science, as well as due to significant ethical and moral concerns.Those are the words found in new guidance established this week.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
AbbVie and I-Mab announced today that they had entered a global collaboration agreement to develop and commercialize lemzoparlimab (also known as TJC4). The anti-CD47 monoclonal antibody was initially discovered and developed by I-Mab for the treatment of various cancers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.
PRESS RELEASES